Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia

September 30, 2024 05:00 PM AEST | By Cision

Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia — Image source: Kalkine Media

Recent News

'SHANGHAI' Installation Unveiled as Oriental Pearl Tower Greets 100 Mi...

Yunji Has Regained Compliance with Nasdaq's Minimum Bid Price Requirem...

New Oriental to Report First Quarter 2025 Financial Results on October...

Hitachi Completes Acquisition of MA micro automation of Germany, a Lea...

HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR) has completed the dosing of the first patient in the Phase 2 study of DR10624 for the treatment of severe hypertriglyceridemia (SHTG).

The Phase 2 study is a randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of three dose levels of DR10624 in adult SHTG patients, who have mean fasting triglycerides of greater than or equal to 5.65 mmol/L (500 mg/dL) at screening. A total of 72 participants will be enrolled in the study.

"DR10624 is a first-in-class long-acting tri-agonist targeting FGF21R, GLP-1R, and glucagon receptor (GCGR). Developed using Doer Bio's proprietary MultipleBody® platform technology, DR10624 was engineered to exhibit balanced activity for metabolic diseases. In non-clinical studies, DR10624 has demonstrated extraordinary potency in reducing body weight, lowering triglycerides, normalizing blood lipids, and improving liver function." said Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio.

"We're excited to announce the dosing of first patient in our Phase 2 study of DR10624 for the treatment of severe hypertriglyceridemia. Patients with SHTG, particularly those with uncontrolled hypertriglyceridemia, face a heightened risk of developing acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). This Phase 2 study is designed to identify the optimal dose for pivotal Phase 3 clinical trials. We are eager to advance DR10624 as a potential treatment for patients struggling with SHTG". commented Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio.

More information about the Phase 2 clinical trial is available at clinicaltrials.gov (NCT06555640)

About Doer Bio

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio") is a clinical stage biopharmaceutical company that focuses on the discovery and development of multi-domain based multi-specific biotherapeutics to address unmet medical need in the field of metabolic diseases and cancers.

Doer Bio has developed multiple proprietary platform technologies, including xLONGylation®, MultiBody®, AccuBody®, and SMART-VHHBody.

For more information about Doer Bio, please visit www.doerbio.com.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.